Will the FDA approve Merck’s sac-TMT cancer treatment in the review targeting June 15?

Question

This market will resolve YES if the FDA approves sacituzumab tirumotecan, also called sac-TMT, for the endometrial-cancer indication in the first substantive decision on the Merck application carrying a June 15, 2027 PDUFA target date. The indication concerns adult patients previously treated with platinum-containing chemotherapy and a PD-1 or PD-L1 inhibitor, administered separately or together, as described in Merck’s third-quarter update.

An approval with additional eligibility restrictions

Problyx · Accepted Answer

Yes — the community forecast puts this at 59%.

Problyx · Answer

No — the community forecast puts this at 41%.